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We read with great interest the recently published case-control study by Mannacio et al
1
. In 
regard to preoperative clopidogrel administration management, patients were divided into 
three equally matched groups with aim to evaluate whether individually tailored preoperative 
clopidogrel discontinuation management based on platelet function testing may reduce 
postoperative blood loss and transfusion requirements in patients exposed to clopidogrel in 
proximity to surgery
1
. Put briefly, the strategy to guide clopidogrel discontinuation 
management using platelet function testing significantly reduced postoperative bleeding and 
blood consumption
1
. In addition to, platelet function testing based strategy provided shorter 
waiting time for surgery after clopidogrel discontinuation, than it is recommended by the 
current guidelines
1
. Nowadays, different types of devices to measure drug specific platelet 
reactivity are available. Despite some device specific advantages and disadvantages, some 
basic principles in preoperative decision making should inevitably be considered as they are 
applicable to each device providing drug specific platelet function quantification. This study 
certainly adds to the current knowledge, however, some methodological considerations should 
be addressed too. Even though case-control matching was used to reduce the effect of 
potential confounders and calculated propensity scores included preoperative aspirin 
administration management, the lack of aspirin specific platelet function testing remains to be 
the drawback of the study
1
. Noteworthy, multivariate analysis confirmed preoperative aspirin 
as independent predictor for need of 3 or more packed red blood cells (PRBCs)
1
. There is 
evidence that certain patients have an accentuated response to the usual doses of preoperative 
aspirin that may result in increased perioperative blood loss
2, 3
. Recently, our research group 
found that patients who received packed red blood cells (PRBCs) transfusion had significantly 
lower aspirin sensitive platelet function test values compared to the patients not exposed to 
PRBCs (p= 0.002)
3
. Therefore, it seems reasonable to use concomitantly platelet function 
assays sensitive to clopidogrel and aspirin. Growing proportion of patients is being 
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preoperatively exposed to dual antiplatelet therapy (aspirin and clopidogrel). Awidi et 
coworkers found that the combination of aspirin and clopidogrel had greater inhibitory effects 
on platelet aggregation than either agent alone
4
. Furthermore, there is evidence that 
clopidogrel, when administered concomitantly with aspirin reduces the incidence of aspirin 
resistance
5
. Therefore, platelet inhibitory response to aspirin and consequent risk for excessive 
bleeding and transfusion requirements in cases of pronounced platelet inhibition should not be 
underestimated. The influence of aspirin and clopidogrel on bleeding should separately be 
assessed by drug specific platelet function tests, facilitating individual therapeutic approach 
for each antiplatelet agent preoperatively. Prospective studies evaluating the relationship 
between drug specific platelet function test values and outcomes in this particular population 
should provide firm cutoff values that delineate not only bleeding tendency but also proclivity 
towards ischemic events in cases of patients with high on treatment platelet reactivity in 
whom too early discontinuation may cause platelet hyperactivity followed by rebound 
phenomenon that may finally result in ischemic events while awaiting surgery. In this way it 
would be possible to frame “safety window” range in platelet drug specific reactivity. Lower 
bound would delineate bleeding tendency whilst upper bound would delineate proclivity 
towards ischemic events. We congratulate authors on this timely and elegant study. Further 
studies using platelet function testing and sufficiently powered to assess possible benefits in 
clinical outcomes are needed in order to provide the most precise and reliable information 
about benefits and risks of point-of-care guided preoperative administration/discontinuation 
for each antiplatelet agent, thus facilitating individual approach to patients with aim to reduce 
both bleeding and adverse ischemic events.  
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